Trial Profile
A Multicenter, Multinational Clinical Assessment Study for Pediatric Patients With Achondroplasia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia
- Focus Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 15 Apr 2021 According to a BioMarin Pharmaceutical media release, the data from this study was presented at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.
- 15 Apr 2021 Results published in the BioMarin Pharmaceutical Media Release
- 08 Apr 2021 Status changed from recruiting to completed.